FY2027 EPS Estimates for Insulet Raised by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Analysts at Leerink Partnrs increased their FY2027 EPS estimates for Insulet in a note issued to investors on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings per share of $7.10 for the year, up from their prior estimate of $6.89. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s FY2028 earnings at $8.86 EPS and FY2029 earnings at $10.58 EPS.

A number of other research firms also recently commented on PODD. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 price objective for the company in a report on Tuesday. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Barclays lifted their price objective on shares of Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 30th. Finally, Citigroup lifted their price objective on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $306.53.

Insulet Stock Performance

Insulet stock opened at $314.46 on Monday. The company has a market cap of $22.13 billion, a PE ratio of 54.31, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a fifty day moving average price of $259.46 and a two-hundred day moving average price of $264.81. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 12 month low of $160.19 and a 12 month high of $323.00.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same quarter last year, the company earned $0.73 earnings per share. The business’s quarterly revenue was up 28.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after purchasing an additional 178,976 shares in the last quarter. Baillie Gifford & Co. increased its stake in Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares in the last quarter. Geode Capital Management LLC increased its stake in Insulet by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock worth $463,347,000 after purchasing an additional 40,566 shares in the last quarter. American Century Companies Inc. increased its stake in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Finally, Norges Bank purchased a new position in Insulet in the 4th quarter worth about $248,806,000.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. The trade was a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.